Literature DB >> 11781832

PARP co-activates B-MYB through enhanced phosphorylation at cyclin/cdk2 sites.

G Santilli1, M N Cervellera, T K Johnson, R E Lewis, S Iacobelli, A Sala.   

Abstract

PARP is a multifunctional protein that can affect genome stability, transcription control, telomere length and cell death. Recently we have reported that PARP binds to and enhances B-MYB transactivating potential. B-MYB is a potentially oncogenic transcription factor involved in mammalian cell proliferation, survival and differentiation. B-MYB gene expression is growth regulated and B-MYB protein is phosphorylated during S phase by cyclin A or E/cdk2 kinase, resulting in augmented transactivating potential. Here we show that PARP induces phosphorylation of B-MYB protein at cdk2 phosphorylation sites, since a B-MYB protein with mutated cdk2 phosphorylation sites is refractory to PARP-induced phosphorylation and co-activation in mammalian cells. We propose that PARP functions as a B-MYB co-factor by promoting cyclin/cdk2-dependent B-MYB phosphorylation. These results highlight a novel role for PARP as a factor that integrates cyclin-dependent kinases signaling with gene transcription.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11781832     DOI: 10.1038/sj.onc.1204943

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

1.  B-Myb promotes S-phase independently of its sequence-specific DNA binding activity and interacts with polymerase delta-interacting protein 1 (Pdip1).

Authors:  Eugen Werwein; Thore Schmedt; Heiko Hoffmann; Clemens Usadel; Nora Obermann; Jeffrey D Singer; Karl-Heinz Klempnauer
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

2.  Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2.

Authors:  Lisa K Pierson-Mullany; Carol A Lange
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

3.  The B-MYB transcriptional network guides cell cycle progression and fate decisions to sustain self-renewal and the identity of pluripotent stem cells.

Authors:  Ming Zhan; Daniel R Riordon; Bin Yan; Yelena S Tarasova; Sarah Bruweleit; Kirill V Tarasov; Ronald A Li; Robert P Wersto; Kenneth R Boheler
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

4.  Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?

Authors:  Amanda Lovato; Lawrence Panasci; Michael Witcher
Journal:  Front Pharmacol       Date:  2012-12-27       Impact factor: 5.810

5.  Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer.

Authors:  Gabriele Corda; Gianluca Sala; Rossano Lattanzio; Manuela Iezzi; Michele Sallese; Giorgia Fragassi; Alessia Lamolinara; Hasan Mirza; Daniela Barcaroli; Sibylle Ermler; Elisabete Silva; Hemad Yasaei; Robert F Newbold; Paola Vagnarelli; Marcella Mottolese; Pier Giorgio Natali; Letizia Perracchio; Jelmar Quist; Anita Grigoriadis; Pierfrancesco Marra; Andrew N Tutt; Mauro Piantelli; Stefano Iacobelli; Vincenzo De Laurenzi; Arturo Sala
Journal:  J Pathol       Date:  2016-12-29       Impact factor: 7.996

Review 6.  MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis.

Authors:  Julian Musa; Marie-Ming Aynaud; Olivier Mirabeau; Olivier Delattre; Thomas Gp Grünewald
Journal:  Cell Death Dis       Date:  2017-06-22       Impact factor: 8.469

7.  Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes.

Authors:  Julian Musa; Florencia Cidre-Aranaz; Marie-Ming Aynaud; Martin F Orth; Maximilian M L Knott; Olivier Mirabeau; Gal Mazor; Mor Varon; Tilman L B Hölting; Sandrine Grossetête; Moritz Gartlgruber; Didier Surdez; Julia S Gerke; Shunya Ohmura; Aruna Marchetto; Marlene Dallmayer; Michaela C Baldauf; Stefanie Stein; Giuseppina Sannino; Jing Li; Laura Romero-Pérez; Frank Westermann; Wolfgang Hartmann; Uta Dirksen; Melissa Gymrek; Nathaniel D Anderson; Adam Shlien; Barak Rotblat; Thomas Kirchner; Olivier Delattre; Thomas G P Grünewald
Journal:  Nat Commun       Date:  2019-09-11       Impact factor: 14.919

8.  Molecular response to PARP1 inhibition in ovarian cancer cells as determined by mass spectrometry based proteomics.

Authors:  Alexandra Franz; Fabian Coscia; Ciyue Shen; Lea Charaoui; Matthias Mann; Chris Sander
Journal:  J Ovarian Res       Date:  2021-10-22       Impact factor: 4.234

9.  ADP ribosylation by PARP-1 suppresses HOXB7 transcriptional activity.

Authors:  Xinyan Wu; Stephan Ellmann; Ethel Rubin; Minchan Gil; Kideok Jin; Liangfeng Han; Hexin Chen; Erika M Kwon; Jianhui Guo; Hyo Chol Ha; Saraswati Sukumar
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

10.  B-Myb switches from Cyclin/Cdk-dependent to Jnk- and p38 kinase-dependent phosphorylation and associates with SC35 bodies after UV stress.

Authors:  E Werwein; M Dzuganova; C Usadel; K-H Klempnauer
Journal:  Cell Death Dis       Date:  2013-02-28       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.